Biopharma FDA Healthcare Provider Side effects 
PM360
JUNE 11, 2022
For example, everyone must be steeped in both FDA and FTC guidelines. Regardless of the tactics and strategies employed, I would encourage more biopharma professionals to get personally involved in patient engagement programs. Once you choose a patient partner, transparency is tantamount to building a successful working relationship.
PM360
JULY 13, 2023
The FDA has granted Fast Track Designation for our HER2-targeted ADC, ARX788, and we are enrolling the signal-seeking ACE-Breast-03 Phase 2 clinical study in post-Enhertu mBC patients throughout 2H 2023. Not only can we design drugs better, but we can understand their effects better to engineer small molecules in a more efficient way.
Expert insights. Personalized for you.
59 
Let's personalize your content